## AUROBINDO PHARMA LIMITED

DETAILS OF STOCK OPTIONS PURSUANT TO SECURITIES AND EXCHANGE BOARD OF INDIA (SHARE BASED EMPLOYEE BENEFITS) REGULATIONS, 2014

1. Disclosures in terms of Guidance note on accounting for employee share-based payments issued by ICAI:

Disclosed in the Notes to financial statements - Refer to Note 31 (Share Based Payments) of Standalone Financials Statements 2019-20, page Nos. 188 and 189 of the Annual Report 2019-20.

2. Material Changes in the Scheme:

Nil

**3.** Diluted EPS

Diluted EPS	: Rs.31.96
Adjusted Diluted EPS	: Rs.31.96

4. Details related to Employee Stock Option Scheme:

DESCRIPTION	Particulars	
<ul> <li>(i) A description of each ESOS that existed at any time during the year, including the general terms and conditions of each ESOS, including -</li> </ul>	Employee Stock Option Plan 'ESOP-2006'	
a. Date of Shareholders approval	18.09.2006	
b. Total Number of options approved under ESOS	71,29,515*	
c. Vesting requirements	Completion of continuous service, except in case of disability, death and retirement:	
	After one year10%After two years15%After three years25%After four years50%	
d. Exercise Price or pricing formulae		
December 16, 2011	Rs. 45.80*	
January 09, 2013	Rs. 100.35*	
January 28, 2013	Rs. 93.70*	
August 9, 2013	Rs. 80.65*	
e. Maximum term of Options granted	6 years	
f. Source of shares	Primary	
g. Variation in terms of Option	Not Applicable	
(ii) Method used to account for ESOS-	Fair Value	
(iii) The difference between the employee compensation cost so computed and the employee compensation cost that shall have been recognized if it had used the fair value of the options.	Not applicable as accounting is done on fair value method	

The impact of	this difference on profits	PAT	Rs. 18,727.4 Million	
	the company shall also be	Less: Additional cost	Nil	
disclosed		Based on Fair Value		
		Adjusted PAT	Rs. 18,727.4 Million	
		Adjusted EPS	Rs.31.96	
(iv) Option movemen	t during the year-			
	Particulars	Det	tails	
Number of op	otions outstanding at the	23,000		
beginning of the	e period	-,		
Number of optic	ons granted during the year	Nil		
Number of o	otions forfeited / lapsed	Ν	lil	
during the year				
Number of options vested during the year			lil	
•	tions exercised during the	23,000		
year				
	ares arising as a result of	23,000		
exercise of opti				
-	d by exercise of options	18,54,950		
the company	e is implemented directly by			
	the Trust during the year	Not Applicable		
from exercise p	<b>u</b>	Νοι Αρριταδίε		
	ions outstanding at the end	Nil		
of the year				
-	ions exercisable at the end	Nil		
of the year				
(v) Weighted Averag	e Exercise Price (Rs.)	N.A		
(on outstanding o				
5 5	e Fair Value (Rs.)	N.A		
(on outstanding o	•			
	letails (name of employee, c		options granted during	
the year, exercise price) of options granted to				
•	Personnel/Key Managerial Pe	-		
Name of employee	Designation	No. of options	Exercise Price	
		granted during the		
Nil	Nil	year Nil	Nil	
	ee who receives a grant in ar			
of option granted dur	-	יז טווב צבמו טו טרנוטוו מו		
Name of employee	Designation	No. of options	Exercise Price	
inanie of employee	Sesignation	granted during the		
		year		
Nil	Nil	Nil	Nil	
	ees who were granted option,	during any one year, e		
of the issued capital (excluding outstanding warrants and conversions) of the company at the				
time of grant.				
Name of employee	Designation	No. of options	Exercise Price	
		granted during the		
		year		
Nil	Nil	Nil	Nil	

(vii) A description of the method and significant assumptions used during the year to estimate the fair value of options including the following information.		
(a) the weighted-average values of share price, exercise price,		
expected volatility, expected option life, expected dividends,		
the risk-free interest rate and any other inputs to the model;		
Weighted Average Values of share price	Rs.80.65*	
Exercise Price		
December 16, 2011	Rs. 45.80*	
January 09, 2013	Rs.100.35*	
January 28, 2013	Rs. 93.70*	
August 28, 2013	Rs. 80.65*	
Expected Volatility		
Expected Option Life	NA	
Risk -free interest rate (%)		
Expected Dividend yield		
(b) the method used and the assumptions made to incorporate	NA	
the effects of expected early exercise;		
(c) how expected volatility was determined, including an	NA	
explanation of the extent to which expected volatility was		
based on historical volatility; and		
(d) whether and how any other features of the option grant	NA	
were incorporated into the measurement of fair value, such as		
a market condition		
(viii) Disclosures in respect of grants made in three years prior	NA	
to IPO under each ESOS.		

\* The total number of options and exercise price adjusted on account of 1:1 bonus issue of equity shares during the year 2015-16.

\* The exercise price for all the options is equal to market price.

For and on behalf of the Board

Place: Hyderabad Date : 3 June 2020 K. RAGUNATHAN Chairman